INTRODUCTION
High dose intravenous methylprednisolone (IVMP) accelerates recovery from acute relapses in multiple sclerosis (MS) [1] [2] [3] and is a standard treatment for acute deteriorations in MS 4 .
Previous clinical studies suggested that the treatment is less efficient for exacerbations in patients with a progressive course of MS [3] [4] [5] , but to our knowledge, no study so far has directly compared the IVMP effects between patients with relapsing-remitting (RR-MS), secondary progressive (SP-MS) and primary progressive MS (PP-MS). IVMP pulse therapy is generally accepted as a safe treatment without major adverse effects 6 . However, negative effects of methylprednisolone on neuronal survival have recently been shown in an animal model of progressive MS 7 , emphasizing the need for a reevaluation of the current therapy regimen.
Impaired motor performance is a major cause of disability in MS, and therefore transcranial magnetic stimulation (TMS) has been used to evaluate treatment effects. The central motor conduction time (CMCT) is easily obtained by TMS 8 9 , but changes in CMCT do generally not correlate with improved clinical motor deficit after IVMP treatment in MS [10] [11] [12] , since slowing of conduction is not, or only marginally related to clinical function 9 13-15 .
Motor function relates to the number of conducting central motor neurons, which in theory, should be reflected by the size of the TMS response. In practice, however, MEP size parameters (amplitudes and areas) are not sensitive to quantify conduction deficits. Two factors obscure the relation between MEP size and number of conducting central motor neurons, namely (i) desynchronization of the TMS induced motor neuron discharges causing variable degrees of phase cancellation, and (ii) repetitive discharges of spinal motor neurons in response to TMS 16 . Both factors affect MEP size considerably, unpredictably, and vary between subjects and from one stimulus to the next 16 17 . The triple stimulation technique (TST) eliminates the effects of discharge desynchronization and repetitive discharges on TMS responses, such that an accurate quantification of the proportion of conducting central motor neurons is possible 16 . Use of the TST increased the sensitivity to detect a central motor conduction deficit in MS by a factor of 2.86, and the TST response size correlated with the clinical motor deficit of the patients 18 . Moreover, the TST allowed detection of transient small changes of conduction deficits in MS patients related to changing body temperature ("Uhthoff phenomenon"), which correlated well with walking velocity 19 .
In the present study, MS patients receiving IVMP for an acute exacerbation involving the motor system were followed clinically and neurophysiologically with the TST. All patients were examined just prior to the start and at the end of 5 days IVMP; in some of the patients a group.bmj.com on June 22, 2017 -Published by http://jnnp.bmj.com/ Downloaded from 4 second follow-up investigation took place 2 months after the start of IVMP. Our results point to considerable differences of treatment efficacy between patients with different disease courses.
METHODS

Patients
The study was approved by the local ethics committee. All patients gave written informed consent.
Forty-one patients with definite MS 20 were enrolled in the study: 24 patients with relapsingremitting MS (RR-MS), 8 with secondary progressive (SP-MS) and 9 with primary progressive (PP-MS) MS. Disease duration was defined as the time elapsed between the first disease manifestation (determined clinically or by history taking) and the current investigation. All patients suffered from a relapse with clincial involvement of the corticospinal tract to the lower limbs (i.e., hyperreflexia, extensor plantar response, spasticity and/or paresis). A relapse was defined as a newly observed neurological deficit without evidence of spontaneous improvement for at least 24 hours. In all cases, the decision of whether a Methylprednisolone treatment was started or not was taken by clinical neurologists not involved in the study. In the 17 included patients with chronic MS, the disease course was not always known at the start of the treatment and a worsening of symptoms or new symptoms was suspected, so that a treatment was started. In our department, a methylprednisolone treatment is often given in ambiguous clinical situations, because of the low risk of short term adverse effects. Clinical and electrophysiological examinations were performed just before starting methylprednisolone treatment (= day 0; Solu-Medrol 500 mg/d intravenously for 5 consecutive days followed by oral prednisone tapering over 10 days) and at the time of the last methylprednisolone infusion (= day 5). Twenty-eight patients were available for a third investigation 67.6±10.8 days after study begin (= 2 months).
To assess disease-independent effects of IVMP on pyramidal tract function, clinical and electrophysiological examinations were performed on days 0 and 5 as described above in 4 patients presenting with an isolated optic neuritis. Extensive diagnostic work-up (clinical examination, analysis of cerebrospinal fluid, somatosensory and motor evoked potentials, brain MRI) found no evidence of MS in these patients. They were assigned to identical IVMP treatment as the MS patients. hyperreflexia, extensor plantar response and/or spasticity) was noted. In MS patients, the clinically most affected leg was chosen for electrophysiological testing; in patients with isolated optic neuritis one leg was chosen randomly. The same examiner reassessed muscle force and pyramidal signs before neurophysiological testing on day 5 and after 2 months.
Electrophysiological methods
A Viking Select apparatus (Nicolet, Madison, Wisconsin, USA) was used for the recordings.
Bandpass filters were 2 Hz -10kHz. Recordings were taken from the abductor hallucis muscle (AH) using silver electrodes (diameter 0.8 cm) in a belly-tendon montage. The TST to the lower limbs was described previously in detail 24 (see Fig. 1 for a summary of the principle). In short, TMS was combined with supramaximal stimuli of the tibial nerve at the ankle and the sciatic nerve at the gluteal fold 24 . The peripheral stimuli were given using the two stimulators of the Viking EMG machine. The TST was achieved by using a dedicated software package for the Nicolet Viking apparatus provided by Judex AS (Aalborg, DK).
The delays between the three stimuli were calculated as follows:
• Delay I (brain-ankle) = minimal MEP latency -CMAP ankle latency
• Delay II (gluteal-ankle) = CMAP gluteal latency -CMAP ankle latency The TST test curve was then compared to the TST control curve, obtained by replacing the TMS by a maximal electrical stimulus to the sciatic nerve at the gluteal fold with appropriate delays (delay I = delay II = CMAP gluteal latency -CMAP ankle latency) 24 .
Statistics
The TST amplitude was expressed as the amplitude ratio of TST test :TST control (termed TST amplitude ratio). To test differences between group means, non-parametric tests were applied (Kruskal Wallis test for multiple unpaired groups, Mann Whitney U for unpaired two group comparisons, Wilcoxon signed rank test for paired two-group comparisons). The null hypothesis was rejected at the 0.05 level of significance.
RESULTS
Baseline measurements (day 0)
Clinical and electrophysiological characteristics of the patients are summarized in table 1. MS groups differed significantly for age (p = 0.005) and disease duration (p = 0.001). Most patients were treated and investigated within 2 months of the first possible symptom of the current relapse. In some patients, treatment was started later, caused by differential referral patterns to our centre (see ranges in table 1). It is noteworthy however that nonparametric testing revealed no significant difference in relapse duration before treatment between the patient groups (p = 0.2). At the time of the investigation, only one SP-MS patient was under simultaneous immune-modulatory treatment (beta interferon).
The mean EDSS score was higher for SP-MS than RR-MS patients (p = 0.001), whereas it did not differ significantly between P-MS and RR-MS (p = 0.18) and between P-MS and SP-MS (p = 0.09). Weakness of the target limb was generally mild to moderate (≥ grade M4) and did not differ significantly between the MS groups (p = 0.2). Apart from impaired vision, the clinical examination was normal in isolated optic neuritis patients.
The mean TST amplitude ratio was reduced in all MS groups, but normal in patients with isolated optic neuritis (lower normal limit = 88.4% group 
Long-term follow-up (day 5 vs 2 months)
Eighteen RR-MS patients, 7 SP-MS patients and 3 PP-MS patients without further clinicial relapses were available at two months for the third investigation. Five RR-MS and 2 SP-MS patients had started immune-modulatory treatment in the meantime (6 beta interferon, 1 glatirameractetate). No statistically significant changes of muscle force and electrophysiological parameters where found compared to day 5 (Fig. 3) ; and the clinical examination remained basically unchanged.
DISCUSSION
We performed a clinical and neurophysiological follow-up in RR-MS, SP-MS and PP-MS patients receiving IVMP for an acute exacerbation involving the motor system. The principal findings were: i) in RR-MS and SP-MS patients, a significant increase of the number of conducting central motor neurons (reflected by an increased TST amplitude ratio) was found after 5 days of treatment, paralleling an increase of muscle force. At the 2 months follow-up, there was no further significant improvement or deterioration, with a stabilisation of TST amplitude ratio and muscle force. ii) In PP-MS patients, the treatment caused no significant changes of TST amplitude ratio and muscle force. iii) CMCT did not change significantly in any MS patient group.
An untreated control patient group was not included in our study, because we judged unethical to exclude patients from a treatment considered as a standard therapeutic approach In these patients, whose central motor conduction was unaffected, we observed neither clinical nor neurophysiological changes after IVMP treatment. Likewise, TST amplitude ratio did normally not change in MS patients not improving clinically from the IVMP treatment ("non-responders").
The increase of TST amplitude ratio during the IVMP treatment observed in our RR-MS and SP-MS patients is best explained by the reduction of a central motor conduction block. Conduction block is an important cause of conduction failure and clinical deficit in acute demyelination 15 25 . It can result from segmental demyelination (which would not immediately respond to steroid treatment), but may also be the consequence of oedema and of inflammatory cytokines 15 26 . IVMP has marked anti-oedematous, anti-inflammatory, as well as membrane stabilizing properties 4 27 . The rapidly occurring reduction of conduction deficit in our RR-MS and SP-MS patients could thus readily be explained. Theoretically, an increase of TST amplitude ratio could also be related to an increase of cortical excitability. However, changes in cortical excitability were previously not found after methylprednisolone treatment of acute relapses (dosage: 1 g/day for 5 days), using the resting motor threshold as a measure of excitability 10 . In the present study, resting motor threshold was only determined in a small number of patients, where it remained unchanged (results not shown). Taken together, it is unlikely that changes of cortical excitability explain the present results.
Several factors may account for the lack of electro-clinical improvement in the PP-MS patient group. First, from histo-pathological 28 and MRI studies [29] [30] [31] , there is increasing evidence that acute inflammation is less prominent in this group of MS patients, resulting in limited efficacy of IVMP. Second, axonal loss might be more substantial in PP-MS than in SP-MS and RR-MS 32 and conduction deficits caused by axonal loss are not likely to change rapidly in response to IVMP, or to any other treatments. The TST quantifies the number of conducting axons, but a reduction of TST amplitude does not differentiate between loss of axons and conduction block 18 . The lack of improvement in follow-up investigations is well in line with axonal loss having taken place, although persistent conduction block cannot be excluded. Our finding of reduced efficacy of IVMP in PP-MS corresponds well with previous clinical observations of less frequent and less pronounced IVMP effects in progressive patients 3 5 . Nevertheless, the present data do not rule out beneficial effects of IVMP, because further deterioration could have occurred in untreated patients 5 , and because the possibility of dose-dependent effects in high dose regimens 10 were not investigated.
So far, only a few studies used MEPs for objective assessment of the IVMP effects in MS patients [10] [11] [12] . None of these studies analysed MEP amplitudes, because the size of conventional MEPs is inaccurate to measure conduction deficits. Use of the TST circumvents this problem, and is able to demonstrate IVMP associated changes in central motor conduction deficits. It shows considerable differences of treatment efficacy between patients with different disease courses. treatment [10] [11] [12] . While these studies generally found an association between overall disease severity and CMCT, a relationship between the change of the clinical motor deficit of the investigated limb and of the corresponding CMCT could not be demonstrated in any of these studies. In the present study, CMCT did not change significantly in any MS patient group, emphasizing the lack of sensitivity of this measure, and of a relation between CMCT and conduction deficit 9 18 24 . We have previously observed that prolongations of CMCT relate to diseases course (relapsing-remitting vs. chronic progressive MS) but not to the motor deficit of a given patient 13 .
Our results suggest a limited efficacy of IVMP for acute exacerbations in PP-MS patients. Overall the changes in CMCT did not reach significance in any MS group, although there was a clear decrease of CMCT in some patiens as shown here for PP-MS. Note that the distance between the two negative deflections of the TST recording does not directly reflect CMCT, but depends on the individually calculated delay I and II. 
